

August 01, 2025

To,
National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra-Kurla Complex,
Bandra (East), Mumbai-400 051
Symbol: JLHL

To,
BSE Limited
P. J. Towers,
25th Floor, Dalal Street, Fort
Mumbai 400 001
Code: 543980

Subject: Investor Presentation for the quarter ended June 30, 2025

Reference: Unaudited Financial Results for the quarter ended June 30, 2025 (Standalone and Consolidated) of the Company.

Dear Sir/ Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time, please find the enclosed investor presentation for the Unaudited (Standalone and Consolidated) Financial Results for the quarter ended June 30, 2025.

This will also be available on the Company's Website at www.jupiterhospital.com.

You are requested to kindly take the afore-mentioned on record and oblige.

Thanking You,

For JUPITER LIFE LINE HOSPITALS LIMITED

Suma Upparatti
Company Secretary and Compliance Officer

IN THE PINK OF HEALTH.



Jupiter Life Line Hospitals Limited

Results Presentation - Q1FY26

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Jupiter Life Line Hospitals Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward looking statements concerning the Company’s future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.

Dr. Ankit Thakker JMD & CEO



"We are pleased to report a strong performance in Q1FY26, with Total Income of Rs 347.6 crore along with an EBITDA of Rs 78.1 cr, supported by improved occupancy levels across all units.

Our new projects are progressing as per plan, with Dombivli expected to be commissioned in less than a year from now in Q1FY27. The second Pune hospital excavation is progressing as per plan with construction set to begin from Q3FY26.

We have commissioned our 1.2 MW solar power plant in Madhya Pradesh, which will add to our existing renewable energy capacity of 5.6 MW of wind energy. Jupiter remains committed to making investments to offset its carbon footprint in pursuit of its sustainability goals.

Recognising the substantial demand-supply mismatch in Western India, we remain focused on exploring strategic expansion opportunities in the region. We have taken on some debt on our books to be ready to capitalize on a suitable opportunity as it arises. This finance cost along with increased depreciation of the ongoing investments will mean that the gap between EBITDA and PBT is expected to be wider in the times to come."

Patient First

Key Performance Highlights of Q1FY26

Total Income

Rs 347.6 cr

 **20.5 % YoY**

1 IPD and OPD revenue grew by 19.6% and 15.5% YoY respectively, indicating strong service utilisation across the hospitals

4 Finance cost increased by Rs 7.2 cr due to debt taken for expansion projects

EBITDA

Rs 78.1 cr


 **19.6 % YoY**

2 Overall patient volumes increased by 11.7% YoY, reflecting consistent growth across the network

5 Total Project Capex for Q1 FY26 stood at ~Rs 40 cr

PAT

Rs 43.9 cr


 **1.6 % YoY**

3 Depreciation has increased by Rs 10.2 cr primarily due to capitalisation of newly added beds

6 Commissioned a 1.2 MW solar power plant in Madhya Pradesh

Q1FY26 Performance Highlights


Rs in Cr




*Jupiter Pharmacy was incorporated as Jupiter Hospital Pharmacy Pvt. Ltd. and post receipt of statutory licenses is being consolidated line-by-line

Q1FY26 Operating Metrics


Operational Bed Capacity⁽¹⁾




Average Occupancy Rate⁽²⁾




IPD & OPD Volumes ('000)⁽³⁾




ARPOB⁽⁴⁾



ALOS (in Days)⁽⁵⁾



Payor Mix



ARPOB rounded off to the nearest hundred

1) Operational beds includes census beds (bed available for mid-night occupancy such as intensive care units ("ICUs"), wards etc.) and non-census beds (all other bed available other than census beds, such as day-care beds, casualty beds etc.) (2) Average occupancy rate is calculated as census occupied bed days (i.e. midnight census of occupied census beds during the period) divided by available census bed days (i.e. census bed capacity multiplied by the applicable days in the relevant period) (3) Out-patient volume refers to the total number of Out-patient bills generated in a specific period. Inpatient volume refers to the total number of inpatient discharge in a specific period irrespective of admission date. (4) ARPOB is calculated as income from hospital services divided by census occupied bed days (i.e. midnight census of occupied census beds during the period) (5) ALOS is the average length of stay of patients in a specific period, calculated as census occupied bed days (i.e. midnight census of occupied census beds during the period) divided by inpatient volume.

Consolidated Profit & Loss Statement

| Profit and Loss (in Rs. cr) | Q1FY26 | Q1FY25 | YoY | Q4FY25 | QoQ | FY25 |
|-----------------------------|--------------|--------------|--------------|--------------|--------------|----------------|
| Revenue from Operations | 344.5* | 284.5 | 21.1% | 323.1 | 6.6% | 1,245.4 |
| Other Income - Operational | 3.1 | 4.1 | | 3.6 | | 16.1 |
| Total Income | 347.6 | 288.6 | 20.5% | 326.7 | 6.4% | 1,261.5 |
| Cost of Goods Sold | 68.3 | 50.2 | | 61.1 | | 230.1 |
| Gross Profit | 279.3 | 238.4 | 17.2% | 265.6 | 5.1% | 1,031.4 |
| Gross Profit Margin | 80.3% | 82.6% | | 81.3% | | 81.8% |
| Employee Cost | 59.4 | 51.3 | | 53.8 | | 214.5 |
| Professional Fees | 82.7 | 70.2 | | 79.6 | | 306.1 |
| Other Expenses | 59.0 | 51.6 | | 54.0 | | 214.2 |
| EBITDA | 78.1 | 65.3 | 19.6% | 78.3 | -0.2% | 296.6 |
| EBITDA Margin | 22.5% | 22.6% | | 24.0% | | 23.5% |
| Depreciation | 21.2 | 11.0 | | 17.6 | | 57.0 |
| EBIT | 56.9 | 54.3 | 4.8% | 60.6 | -6.1% | 239.6 |
| EBIT Margin | 16.4% | 18.8% | | 18.6% | | 19.0% |
| Other Income - Finance | 12.9 | 6.9 | | 7.0 | | 28.7 |
| Finance Cost | 8.3 | 1.1 | | 5.6 | | 10.6 |
| PBT | 61.5 | 60.1 | 2.3% | 62.1 | -0.9% | 257.7 |
| PBT Margin | 17.7% | 20.8% | | 19.0% | | 20.4% |
| Tax | 17.7 | 15.5 | | 17.2 | | 64.2 |
| PAT | 43.9 | 44.6 | -1.6% | 44.9 | -2.2% | 193.5 |
| PAT Margin | 12.6% | 15.5% | | 13.7% | | 15.3% |
| Basic EPS | 6.69 | 6.80 | | 6.84 | | 29.47 |

- ✓ Depreciation has increased by Rs 10.2 cr primarily due to capitalisation of newly added beds
- ✓ Finance cost increased by Rs 7.2 cr due to debt taken for expansion projects

Scaling up for better care: Setting up New hospitals

| Location | Expected Bed Addition Phase I | Expected Bed Addition Phase II | Total Bed Capacity | Capex Estimated (Rs in cr) | Expected to Operationalise | Current Status of Phase I |
|---------------------|-------------------------------|--------------------------------|--------------------|----------------------------|----------------------------|-------------------------------------|
| Dombivli | 200-220 | 280-300 | 500 | 500 | Q1FY27 | Construction is on track |
| Pune II (Bibwewadi) | 200-220 | 280-300 | 500 | 500 | CY28 | Construction will begin from Q3FY25 |
| Mira - Bhayandar | 150-170 | 130-150 | 300 | 400 | CY29 | Under regulatory approval process |

Total Existing Beds

1,061

+

Addition of Beds

~1,440*

=

Total Beds Capacity

~2,500



Jupiter Life Line Hospitals Limited

CIN: L85100MH2002PLC137908

investor.relations@jupiterhospital.com



Strategic Growth Advisors Pvt. Ltd.

CIN: U74140MH2010PTC204285

Mandar Chavan / Rahul Agarwal
mandar.chavan@sgapl.net / rahul.agarwal@sgapl.net
+91 96993 82195 / +91 98214 38864

Thank You